Veterinary Medicines

Febrivac 3-Plus injektioneste, suspensio

Authorised
  • Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
  • Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated
  • Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
  • Clostridium botulinum, type C, toxoid
  • Mink enteritis virus, strain E-MINK F1, Inactivated
Download as PDF

Product identification

Medicine name:
Febrivac 3-Plus injektioneste, suspensio
Active substance:
  • Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
  • Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated
  • Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
  • Clostridium botulinum, type C, toxoid
  • Mink enteritis virus, strain E-MINK F1, Inactivated
Target species:
  • Mink
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Pseudomonas aeruginosa, serotype 6, strain EP2, Inactivated
    8.00
    log10cell count
    /
    1.00
    millilitre(s)
  • Pseudomonas aeruginosa, serotype 7/8, strain EP1, Inactivated
    8.00
    log10cell count
    /
    1.00
    millilitre(s)
  • Pseudomonas aeruginosa, serotype 5, strain EP3, Inactivated
    8.00
    log10cell count
    /
    1.00
    millilitre(s)
  • Clostridium botulinum, type C, toxoid
    0.50
    unit(s)
    /
    1.00
    millilitre(s)
  • Mink enteritis virus, strain E-MINK F1, Inactivated
    4.00
    log10 50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI20CL01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Finland
Package description:
  • 500 ml vial
  • 250 ml vial
  • 50 ml vial

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Complete application (stand-alone)
Marketing authorisation holder:
  • CZ Vaccines S.A.U.
Marketing authorisation date:
Manufacturing sites for batch release:
  • IDT Biologika GmbH
Responsible authority:
  • Finnish Medicines Agency
Authorisation number:
  • 13860
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Finnish (PDF)
Published on: 1/09/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Finnish (PDF)
Published on: 1/09/2025
Download